.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,147,852

« Back to Dashboard

Claims for Patent: 8,147,852

Title:Modified azole compounds as antifungal and antibacterial agents
Abstract: The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. ##STR00001## where the values for R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined herein.
Inventor(s): Borgers; Marcel (Knokke, BE), van Geffen; Maarten (Beerse, BE), Ausma; Jannie (Goirle, NL)
Assignee: Barrier Therapeutics, Inc. (Princeton, NJ)
Application Number:12/108,262
Patent Claims: 1. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and comprises a compound of the formula ##STR00007##

2. The method according to claim 1, wherein the pharmaceutical composition further comprises miconazole nitrate.

3. The method according to claim 1, wherein the pharmaceutical composition further comprises 2,6-di-tert-butyl-4-methylphenol.

4. The method according to claim 1, wherein the pharmaceutical composition further comprises zinc oxide.

5. The method according to claim 1, wherein the pharmaceutical composition further comprises a petrolatum.

6. The method according to claim 5, wherein the petrolatum is white petrolatum.

7. The method according to claim 1, wherein the pharmaceutical composition further comprises trihydroxystearin.

8. The method according to claim 1, wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida guilliermondi, Candida lusitaniae and Candida krusei.

9. The method according to claim 8, wherein the Candida spp, is Candida albicans.

10. The method according to claim 1, wherein the human is also suffering from diaper rash.

11. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and comprises a compound of the formula ##STR00008## miconazole nitrate; zinc oxide; white petrolatum; and trihydroxystearin.

12. The method according to claim 11, wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida guilliermondi, Candida lusitaniae and Candida krusei.

13. The method according to claim 12, wherein the Candida spp, is Candida albicans.

14. The method according to claim 11, wherein the human is also suffering from diaper rash.

15. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and consists of a compound of the formula ##STR00009## miconazole nitrate; zinc oxide; white petrolatum; trihydroxystearin; and optionally a fragrance.

16. The method according to claim 15, wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida Candida Iusitaniae and Candida krusei.

17. The method according to claim 16, wherein the Candida spp, is Candida albicans.

18. The method according to claim 15, wherein the human is also suffering from diaper rash.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc